Tech Company Financing Transactions

XyloCor Therapeutics Funding Round

XyloCor Therapeutics closed a $41.9 million Series A venture capital round on 3/24/2021. Backers included Fountain Healthcare Partners, Life Sciences Partners and Longwood Fund.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
The company intends to use the funds to expand its clinical development program for XC001, an investigational gene therapy designed to promote the growth of new blood vessels in the heart, with these new blood vessels bypassing diseased blood vessels and improving blood flow in the heart.

Company Information

Company Status
Private & Independent
Mailing Address
76 Longview Ln.
Newtown Square, PA 19073
Email Address
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options.
XyloCor Therapeutics LinkedIn Company Profile
Social Media
XyloCor Therapeutics Company Twitter Account
Company News
XyloCor Therapeutics News
XyloCor Therapeutics on Facebook
XyloCor Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Albert Gianchetti
  Albert Gianchetti LinkedIn Profile  Albert Gianchetti Twitter Account  Albert Gianchetti News  Albert Gianchetti on Facebook
Chief Medical Officer
Rickey Reinhardt
  Rickey Reinhardt LinkedIn Profile  Rickey Reinhardt Twitter Account  Rickey Reinhardt News  Rickey Reinhardt on Facebook
VP - Finance
Michael Carson
  Michael Carson LinkedIn Profile  Michael Carson Twitter Account  Michael Carson News  Michael Carson on Facebook
VP - Manufacturing
Alexander Gaidamaka
  Alexander Gaidamaka LinkedIn Profile  Alexander Gaidamaka Twitter Account  Alexander Gaidamaka News  Alexander Gaidamaka on Facebook
VP - Operations
Dawn Byrnes
  Dawn Byrnes LinkedIn Profile  Dawn Byrnes Twitter Account  Dawn Byrnes News  Dawn Byrnes on Facebook
VP - R & D
Howard Dittrich
  Howard Dittrich LinkedIn Profile  Howard Dittrich Twitter Account  Howard Dittrich News  Howard Dittrich on Facebook



Browse more venture capital transactions:

Prev: 3/24/2021: Lev venture capital transaction
Next: 3/24/2021: Meatable venture capital transaction


Share this article


Where The Data Comes From

We do our best to record every notable VC transaction. All VC database entries on this site come from news reports and company announcements. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary